Electra Therapeutics, Inc.
Research Electra Therapeutics, Inc. (ETRA) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerETRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Financial periodQ2 2026
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 61.98M | -USD 61.22M | n/a | -1.8 | USD 33.01M | USD 2.09M | -USD 30.33M |
| FY2024 | USD 0 | -USD 24.79M | -USD 26.00M | n/a | -0.63 | USD 14.79M | USD 0 | -USD 103.26M |
About Electra Therapeutics, Inc.
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies;
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Electra Therapeutics, Inc. do?
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer.